Filing Flows › Nuo Therapeutics (AURX) › Q2 2026 › vs Q2 2025
Nuo Therapeutics (AURX) Q2 2026 vs Q2 2025 (year over year)
Nuo Therapeutics's revenue rose $1.1M (+153%) from $700K in Q2 2025 to $1.8M in Q2 2026.
Nuo Therapeutics, Q2 2026: revenue $1.8M (+153% year over year), operating margin -9.4%, net loss $278K, operating cash flow −$236K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| License | $78K | $75K | $3K | +4% |
| Revenue | $1.8M | $700K | $1.1M | +153% |
| Net loss | $278K | $650K | −$372K | -57% |
| Costs & expenses | $2.0M | $1.4M | $694K | +51% |
| Operating costs | $1.9M | $1.4M | $583K | +43% |
| Interest & other, net | $111K | −$2K | $113K | — |
| Cost of revenue | $599K | $159K | $440K | +276% |
| Operating expenses | $1.3M | $1.2M | $144K | +12% |
| Operating cash sources | $304K | −$216K | $520K | — |
| Depreciation | $26K | $23K | $3K | +14% |
| Share-based compensation | $41K | $23K | $18K | +79% |
| Cash used in operations | $236K | −$262K | $499K | — |
| Net loss absorbed | $278K | $650K | −$372K | -57% |
| Working capital & other | $27K | −$866K | $892K | — |
Questions
How much did Nuo Therapeutics's revenue grow year over year in Q2 2026?
Nuo Therapeutics's revenue rose $1.1M (+153%) from $700K in Q2 2025 to $1.8M in Q2 2026.